Cost-minimization analysis of oral versus intravenous antibiotic treatment for Klebsiella pneumoniae liver abscess
© 2023. The Author(s)..
A cost-minimization analysis was conducted for Klebsiella pneumoniae liver abscess (KLA) patients enrolled in a randomized controlled trial which found oral ciprofloxacin to be non-inferior to intravenous (IV) ceftriaxone in terms of clinical outcomes. Healthcare service utilization and cost data were obtained from medical records and estimated from self-reported patient surveys in a non-inferiority trial of oral ciprofloxacin versus IV ceftriaxone administered to 152 hospitalized adults with KLA in Singapore between November 2013 and October 2017. Total costs were evaluated by category and payer, and compared between oral and IV antibiotic groups over the trial period of 12 weeks. Among the subset of 139 patients for whom cost data were collected, average total cost over 12 weeks was $16,378 (95% CI, $14,620-$18,136) for the oral ciprofloxacin group and $20,569 (95% CI, $18,296-$22,842) for the IV ceftriaxone group, largely driven by lower average outpatient costs, as the average number of outpatient visits was halved for the oral ciprofloxacin group. There were no other statistically significant differences, either in inpatient costs or in other informal healthcare costs. Oral ciprofloxacin is less costly than IV ceftriaxone in the treatment of Klebsiella liver abscess, largely driven by reduced outpatient service costs.Trial registration: ClinicalTrials.gov Identifier NCT01723150 (7/11/2012).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Scientific reports - 13(2023), 1 vom: 16. Juni, Seite 9774 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoong, Joanne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5E8K9I0O4U |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 22.11.2023 published: Electronic ClinicalTrials.gov: NCT01723150 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-36530-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358300878 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358300878 | ||
| 003 | DE-627 | ||
| 005 | 20231226210522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-36530-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358300878 | ||
| 035 | |a (NLM)37328522 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoong, Joanne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost-minimization analysis of oral versus intravenous antibiotic treatment for Klebsiella pneumoniae liver abscess |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 22.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01723150 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a A cost-minimization analysis was conducted for Klebsiella pneumoniae liver abscess (KLA) patients enrolled in a randomized controlled trial which found oral ciprofloxacin to be non-inferior to intravenous (IV) ceftriaxone in terms of clinical outcomes. Healthcare service utilization and cost data were obtained from medical records and estimated from self-reported patient surveys in a non-inferiority trial of oral ciprofloxacin versus IV ceftriaxone administered to 152 hospitalized adults with KLA in Singapore between November 2013 and October 2017. Total costs were evaluated by category and payer, and compared between oral and IV antibiotic groups over the trial period of 12 weeks. Among the subset of 139 patients for whom cost data were collected, average total cost over 12 weeks was $16,378 (95% CI, $14,620-$18,136) for the oral ciprofloxacin group and $20,569 (95% CI, $18,296-$22,842) for the IV ceftriaxone group, largely driven by lower average outpatient costs, as the average number of outpatient visits was halved for the oral ciprofloxacin group. There were no other statistically significant differences, either in inpatient costs or in other informal healthcare costs. Oral ciprofloxacin is less costly than IV ceftriaxone in the treatment of Klebsiella liver abscess, largely driven by reduced outpatient service costs.Trial registration: ClinicalTrials.gov Identifier NCT01723150 (7/11/2012) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Ceftriaxone |2 NLM | |
| 650 | 7 | |a 75J73V1629 |2 NLM | |
| 650 | 7 | |a Ciprofloxacin |2 NLM | |
| 650 | 7 | |a 5E8K9I0O4U |2 NLM | |
| 700 | 1 | |a Yuen, Kah Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Molton, James S |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Cher, Boon Piang |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Kalimuddin, Shirin |e verfasserin |4 aut | |
| 700 | 1 | |a Oon, Jolene |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Barnaby |e verfasserin |4 aut | |
| 700 | 1 | |a Low, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Salada, Brenda M A |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Tau Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Wijaya, Li Min |e verfasserin |4 aut | |
| 700 | 1 | |a Fisher, Dale |e verfasserin |4 aut | |
| 700 | 1 | |a Izharuddin, Ezlyn |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Moorakonda, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Lye, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Archuleta, Sophia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 13(2023), 1 vom: 16. Juni, Seite 9774 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:16 |g month:06 |g pages:9774 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-36530-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 16 |c 06 |h 9774 | ||